Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

CGTX - Cognition Therapeutics, Inc. Stock Price, Fair Value and News

$1.42+0.02 (+1.43%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

CGTX Price Action

Last 7 days

-7.8%

Last 30 days

-49.5%

Last 90 days

373.3%

Trailing 12 Months

144.8%

CGTX Stock Price

CGTX RSI Chart

2025FebMarAprMayJunJulAugSep020406080100

CGTX Valuation

Market Cap

104.3M

Price/Earnings (Trailing)

-3.16

Price/Sales (Trailing)

4.27

EV/EBITDA

-8.18

Price/Free Cashflow

-3.39

CGTX Price/Sales (Trailing)

20232024202502468

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CGTX Fundamentals

CGTX Revenue

Revenue (TTM)

24.4M

Rev. Growth (Yr)

-2.8%

Rev. Growth (Qtr)

39.72%

2021202220232024202510M15M20M25M

CGTX Earnings

Earnings (TTM)

-33.0M

Earnings Growth (Yr)

4.36%

Earnings Growth (Qtr)

20.59%

20212022202320242025-40M-30M-20M-10M0

CGTX Profitability

EBT Margin

-83.92%

Return on Equity

-469.38%

Return on Assets

-168.14%

Free Cashflow Yield

-29.46%

CGTX Investor Care

Shares Dilution (1Y)

83.07%

Diluted EPS (TTM)

-0.66

Revenue Breakdown

As of: Jun 30, 2025
202120222023202420253M4M5M6M7M8M
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2021202220232024202510M12M14M16M18M20M22M24M26M28M
Net sales
YearQ1Q2Q3Q4
202524.1M24.4M00
202422.8M26.7M00
202319.7M021.0M21.9M
202218.7M20.4M23.3M22.2M
202112.5M14.2M15.8M17.4M
202000010.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
 CEO
 WEBSITEcogrx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES22

Cognition Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Cognition Therapeutics, Inc.? What does CGTX stand for in stocks?

CGTX is the stock ticker symbol of Cognition Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cognition Therapeutics, Inc. (CGTX)?

As of Mon Sep 22 2025, market cap of Cognition Therapeutics, Inc. is 104.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGTX stock?

You can check CGTX's fair value in chart for subscribers.

Is Cognition Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGTX is over valued or under valued. Whether Cognition Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Cognition Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGTX.

What is Cognition Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Sep 22 2025, CGTX's PE ratio (Price to Earnings) is -3.16 and Price to Sales (PS) ratio is 4.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGTX PE ratio will change depending on the future growth rate expectations of investors.